The irreversible ERBB1/2/4 inhibitor,
neratinib, down-regulates the expression of ERBB1/2/4 as well as the levels of MCL-1 and BCL-XL.
Venetoclax (ABT199) is a BCL-2 inhibitor. At physiologic concentrations
neratinib interacted in a synergistic fashion with
venetoclax to kill HER2 + and TNBC mammary
carcinoma cells. This was associated with the
drug-combination: reducing the expression and phosphorylation of ERBB1/2/3; in an eIF2α-dependent fashion reducing the expression of MCL-1 and BCL-XL and increasing the expression of
Beclin1 and ATG5; and increasing the activity of the ATM-AMPKα-ULK1 S317 pathway which was causal in the formation of toxic autophagosomes. Although knock down of BAX or BAK reduced
drug combination lethality, knock down of BAX and BAK did not prevent the
drug combination from increasing autophagosome and autolysosome formation. Knock down of ATM, AMPKα,
Beclin1 or over-expression of activated mTOR prevented the induction of autophagy and in parallel suppressed
tumor cell killing. Knock down of ATM, AMPKα,
Beclin1 or
cathepsin B prevented the drug-induced activation of BAX and BAK whereas knock down of BID was only partially inhibitory. A 3-day transient exposure of established
estrogen-independent HER2 + BT474 mammary
tumors to
neratinib or
venetoclax did not significantly alter
tumor growth whereas exposure to [
neratinib +
venetoclax] caused a significant 7-day suppression of growth by day 19. The
drug combination neither altered animal body mass nor behavior. We conclude that
venetoclax enhances
neratinib lethality by facilitating toxic BH3 domain protein activation via autophagy which enhances the efficacy of
neratinib to promote greater levels of cell killing.